Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Takuma Hayashida"'
Autor:
Yosuke Kagawa, MD, Takuma Hayashida, MS, Jie Liu, BS, Shunta Mori, MD, Hiroki Izumi, MD, PhD, Shogo Kumagai, MD, PhD, Hibiki Udagawa, MD, PhD, Noboru Hattori, MD, PhD, Koichi Goto, MD, PhD, Susumu S. Kobayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100462- (2023)
Introduction: EGFR exon 20 insertion mutations account for 5% to 10% of EGFR-mutated NSCLC. CLN-081 (formerly known as TAS6417), a novel covalent EGFR tyrosine kinase inhibitor, exhibits pan-mutation selective efficacy, including exon 20 insertions,
Externí odkaz:
https://doaj.org/article/e3d98b0bb20a49d68b4a9a9c19b6c29e
Autor:
Kaname Nosaki, Jun Sakakibara-Konishi, Ichiro Nakachi, Yoshitaka Zenke, Kageaki Taima, Keisuke Kirita, Kiyotaka Yoh, Shunta Mori, Genichiro Ishii, Shoichi Kuyama, Tatsuro Fukuhara, Shingo Matsumoto, Shogo Kumagai, Hiroki Izumi, Yuji Shibata, Seiji Niho, Noriyuki Ebi, Takaya Ikeda, Jie Liu, Tokiko Nakai, Masahiro Kodani, Haruko Daga, Terufumi Kato, Tetsuya Sakai, Koichi Goto, Atsushi Ohtsu, Kosuke Tanaka, Eri Sugiyama, Atsushi Nakamura, Kana Watanabe, Takuma Hayashida, Isamu Okamoto, Susumu Kobayashi, Kazumi Nishino, Kumiko Hayashi, Naoki Furuya, Hibiki Udagawa, Akira Yamasaki
Publikováno v:
Nature. 600:319-323
Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by oncogenic drivers have substantially improved therapeutic outcomes in patients with non-small-cell lung cancer (NSCLC)1. However, such oncogenic drivers are not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91a19f21c49272718231894afcff24f4
https://doi.org/10.1038/s41586-021-04135-5
https://doi.org/10.1038/s41586-021-04135-5
Autor:
Hiroki, Izumi, Shingo, Matsumoto, Jie, Liu, Kosuke, Tanaka, Shunta, Mori, Kumiko, Hayashi, Shogo, Kumagai, Yuji, Shibata, Takuma, Hayashida, Kana, Watanabe, Tatsuro, Fukuhara, Takaya, Ikeda, Kiyotaka, Yoh, Terufumi, Kato, Kazumi, Nishino, Atsushi, Nakamura, Ichiro, Nakachi, Shoichi, Kuyama, Naoki, Furuya, Jun, Sakakibara-Konishi, Isamu, Okamoto, Kageaki, Taima, Noriyuki, Ebi, Haruko, Daga, Akira, Yamasaki, Masahiro, Kodani, Hibiki, Udagawa, Keisuke, Kirita, Yoshitaka, Zenke, Kaname, Nosaki, Eri, Sugiyama, Tetsuya, Sakai, Tokiko, Nakai, Genichiro, Ishii, Seiji, Niho, Atsushi, Ohtsu, Susumu S, Kobayashi, Koichi, Goto
Publikováno v:
Cancer Cell
Identification of targetable fusions as oncogenic drivers in non-small cell lung cancer has transformed its diagnostic and therapeutic paradigm. In a recent article in Nature, Izumi et al. report the discovery of CLIP1-LTK fusion as a novel oncogenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1c4ee144bddd3a899bbf798b0ecfee7c
https://pubmed.ncbi.nlm.nih.gov/35016028
https://pubmed.ncbi.nlm.nih.gov/35016028
Autor:
Takuma Hayashida, Yosuke Kagawa, Shunta Mori, Liu jie, Yukie Kashima, Kosuke Tanaka, Hibiki Udagawa, Hiroki Izumi, Susumu Kobayashi
Publikováno v:
Cancer Research. 82:5355-5355
Background: EGFR exon 20 insertions are detected in approximately 10% of EGFR mutant non-small cell lung cancer (NSCLC). NSCLC with EGFR exon 20 insertions is resistance to conventional epidermal growth factor receptor tyrosine kinase inhibitors (EGF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48e5f3e4dd1e1e51f4479d37a51987f1
https://doi.org/10.1158/1538-7445.am2022-5355
https://doi.org/10.1158/1538-7445.am2022-5355
Autor:
Hiroki Izumi, Shingo Matsumoto, Jie Liu, Kosuke Tanaka, Shunta Mori, Shogo Kumagai, Takuma Hayashida, Yuji Shibata, Saori Takata, Eriko Tabata, Haruyasu Murakami, Reiko Taki, Satoshi Hara, Tomohiro Sakamoto, Koichi Goto, Susumu S. Kobayashi
Publikováno v:
Cancer Research. 82:5238-5238
Background: The discovery of oncogenic driver has uncovered the pathogenesis of non-small cell lung cancer (NSCLC), and development of corresponding kinase inhibitors has changed treatment strategies and improved survival of patients with druggable o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7f7e1d6660406dcb135e1b945419c34
https://doi.org/10.1158/1538-7445.am2022-5238
https://doi.org/10.1158/1538-7445.am2022-5238
Autor:
Shunta Mori, Hiroki Izumi, Jie Liu, Kosuke Tanaka, Shogo Kumagai, Takuma Hayashida, Yosuke Kagawa, Yuji Shibata, Shingo Matumoto, Koichi Goto, Susumu Kobayashi
Publikováno v:
Cancer Research. 82:5351-5351
Background: CLIP1-LTK was recently discovered as a novel oncogenic gene fusion in non-small cell lung cancer (NSCLC). Lorlatinib, an ALK/ROS1 inhibitor, can inhibit CLIP1-LTK constitutive kinase activity, and showed dramatic and promising efficacy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be6d0a7964ad3c333817f8862b3d76b3
https://doi.org/10.1158/1538-7445.am2022-5351
https://doi.org/10.1158/1538-7445.am2022-5351